Innate Pharma Reveals Early Research on Nectin-4 Targeting Agent IPH45 at 2024 AACR Event

Innate Pharma SA has declared that its pioneering research on the preclinical compound IPH45, a unique Antibody Drug Conjugate that targets Nectin-4 by inhibiting topoisomerase I, will be featured in an oral session at the upcoming 2024 American Association for Cancer Research Annual Meeting. This conference is scheduled from April 5th to 10th and will be hosted in San Diego, California.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

We are thrilled to unveil our research on IPH45 during this year's gathering at the AACR. IPH45 is an innovative Antibody-Drug Conjugate (ADC) that targets neoplastic cells overexpressing the protein Nectin-4, releasing a topoisomerase I blocker. In Prof. Eric Vivier's words, "Our experimental results showed that IPH45 is remarkably effective at curbing tumor proliferation in both laboratory and animal models, while maintaining an acceptable toxicity profile in early-stage tests."

Prof. Vivier, who serves as the Chief Scientific Officer at Innate Pharma and holds a DVM and a Ph.D., continued, "These encouraging outcomes highlight the potential of IPH45 as a groundbreaking avenue in the fight against cancer, anchored by sophisticated advancements in the field of monoclonal antibodies. These positive findings propel us to quickly move forward with IPH45 towards the next phase of clinical testing."

Nectin-4, which is often found at elevated levels on several solid tumors such as those affecting the bladder, breast, lungs, ovaries, and pancreas, provides a strategic therapeutic target due to its minimal presence in healthy tissue. IPH45, representing a new therapeutic option, is an ADC that homes in on Nectin-4 and exhibits manageable safety and notable efficacy against tumors in preclinical settings, bringing it closer to initial trials in humans.

Innate Pharma S.A. stands at the forefront of international clinical-stage biotech enterprises, focusing on the development of innovative cancer immunotherapies. The company's strategy leverages the power of the innate immune response by utilizing therapeutic antibodies, including their advanced ANKET® technology platform.

The company's promising pipeline features several primary projects, such as lacutamab, which is targeting advanced stages of cutaneous T cell lymphomas and peripheral T cell lymphomas; monalizumab, an endeavor partnered with AstraZeneca for the treatment of non-small cell lung cancer; and an array of ANKET® multi-specific NK cell engagers designed to confront various cancer types.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

According to the data provided by the Synapse Database, As of March 7, 2024, there are 40 investigational drugs for the Nectin-4 target, including 24 indications,43 R&D institutions involved, with related clinical trials reaching 76, and as many as 2274 patents.

IPH-45 is an antibody drug conjugate and fusion protein that targets nectin-4, a protein associated with neoplasms. It is being developed by Innate Pharma SA for the treatment of neoplasms. Currently in the preclinical phase, IPH-45 is undergoing testing to determine its safety and efficacy before progressing to clinical trials.